Bahrain authorises emergency use of Evusheld against COVID-19
TDT | Manama
The Daily Tribune – www.newsofbahrain.com
The National Health Regulatory Authority (NHRA) yesterday approved the emergency use of the Evusheld to combat the COVID-19, making Bahrain the first country to utilise the drug.
It will be available to adults 18 years and above, who are immunocompromised or who are taking immunosuppressive drugs, or for individuals with occupations that put them at risk of infection.
The decision follows the evaluation of data provided by the manufacturer AstraZeneca, carried out by the NHRA’s Pharmaceutical Products Regulation department.
Evusheld is made from a mixture of two antibodies, which achieved a “statistically significant decrease in cases of acute or fatal COVID-19 infection” in patients who were not hospitalised and those with symptoms Evusheld ... ‘wonder drug’ ranging from mild to moderate.
Related Posts